Die personalisierte Therapie beim Ovarialkarzinom

Ann-K. Langner; Nina F. Pauly; Beyhan Ataseven; Andreas du Bois

doi:10.1055/s-0043-117422

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2018; 78(01): 34-40
DOI: 10.1055/s-0043-117422

GebFra Magazin

Aktuell diskutiert

Georg Thieme Verlag KG Stuttgart · New York

Die personalisierte Therapie beim Ovarialkarzinom

Ann-K. Langner

,

Nina F. Pauly

,

Beyhan Ataseven

,

Andreas du Bois

Abstract

Full Text

References

Literatur
1 Gesellschaft der epidemiologischen Krebsregister in Deutschland, Robert Koch-Institut. Krebs in Deutschland 2011/2012. 10. Ausgabe. Berlin: 2015
2 Leitlinienprogramm Onkologie (DGK, DGGG, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 2.0 – Oktober 2016. AWMF-Registernummer: 032/035OL. Online: http://www.awmf.org/leitlinien/detailII/032-035OL.html Stand: 14.07.2017
3 Harter P, Hauke J, Heitz F. et al. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarial cancer (OC) patients (AGO TR-1). J Clin Oncol 2016; 34 (Suppl.) Abstr.. 5538
4 Deutsches Konsortium familiärer Brust- und Eierstockkrebs. Informationen. Online: http://www.konsortium-familiaerer-brustkrebs.de/informationen/familiaerer-brust-und-eierstockkrebs/ Stand: 14.07.2017
5 Trimbos B, Timmers P, Pecorelli S. et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102: 982-987
6 du Bois A, Reuss A, Pujade-Lauraine E. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009; 115: 1234-1244
7 du Bois A, Luck HJ, Meier W. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329
8 Harter P, Sehouli J, Lorusso D. et al. LION: Lymphadenectomy in ovarian neoplasms–A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 2017; 35 (Suppl.) 5500-5500
9 Vergote I, Trope CG, Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953
10 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-257
11 Marth C, Zeimet A, Du Bois A. Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery?. Oncology Williston Park 2011; 25: 940 942, 944
12 du Bois A, Marth C, Pfisterer J. et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer 2012; 22: 182-185
13 Fotopoulou C, Sehouli J, Aletti G. et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 2017; 35: 587-590
14 ClinicalTrials.gov. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST). Online: https://clinicaltrials.gov/ct2/show/NCT02828618 Stand: 14.07.2017
15 Perren TJ, Swart AM, Pfisterer J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496
16 Burger RA, Brady MF, Bookman MA. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483
17 du Bois A, Floquet A, Kim J-W. et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374-3382
18 du Bois A, Kristensen G, Ray-Coquard I. et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78-89
19 Grabowski JP, Harter P, Heitz F. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 2016; 140: 457-462
20 Gershenson DM, Bodurka DC, Coleman RL. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35: 1103-1111
21 Okamoto A, Sugiyama T, Hamano T. et al. Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. J Clin Oncol 2014; 32: 5507-5507
22 Gore ME, Hackshaw A, Brady WE. et al. Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). J Clin Oncol 2015; 33: 5528-5528
23 Wilson MK, Pujade-Lauraine E, Aoki D. et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 2017; 28: 727-732
24 Harter P, Hahmann M, Lueck HJ. et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 1324-1330
25 Harter P, Sehouli J, Reuss A. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21: 289-295
26 du Bois A, Vergote I, Ferron G. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017; 35 (Suppl.) 5501-5501
27 Aghajanian C, Blank SV, Goff BA. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-2045
28 Pujade-Lauraine E, Hilpert F, Weber B. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302-1308
29 Ledermann J, Harter P, Gourley C. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392
30 Ledermann JA, Harter P, Gourley C. et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016; 17: 1579-1589
31 Pujade-Lauraine E, Ledermann J, Selle F. et al. Olaparib tablets as maintenace therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/NGOT-Ov21): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet Oncol 2017; 18: 1274-1284 . Online: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(17)30469-2.pdf Stand: 17.08.2017
32 http://www.nasdaq.com. Clovis Oncologyʼs Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial. Online: http://www.nasdaq.com/press-release/clovisoncologys-rucaparib-significantly-improvedprogression-free-survival-in-all-ovariancancer-20170619-00122 Stand: 14.07.2017
33 Mirza MR, Monk BJ, Herrstedt J. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375: 2154-2164
34 ClinicalTrials.gov. Platine, Avastin and OLAparib in 1st Line (PAOLA-1). Online: https://clinicaltrials.gov/show/NCT02477644 Stand: 14.07.2017
35 ClinicalTrials.gov. A study of niraparib maintenance treatment in patients With advanced ovarian cancer following response on front-line platinum-based chemotherapy. Online: https://clinicaltrials.gov/ct2/show/NCT02655016 Stand: 14.07.2017
36 ClinicalTrials.gov. A study of atezolizumab versus placebo in combination With paclitaxel, carboplatin, and bevacizumab in participants with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer (IMagyn050). Online: https://clinicaltrials.gov/ct2/show/NCT03038100 Stand: 14.07.2017
37 ClinicalTrials.gov. ATALANTE: Atezolizumab vs placebo phase III study in late relapse ovarian cancer treated with chemotherapy + bevacizumab (ATALANTE). Online: https://clinicaltrials.gov/ct2/show/NCT02891824 Stand: 14.07.2017
38 ClinicalTrials.gov. A study to examine olaparib maintenance retreatment in patients with epithelial ovarian cancer (OReO). Online: https://clinicaltrials.gov/ct2/show/NCT02855944 Stand: 14.07.2017
39 Liu JF, Barry WT, Birrer M. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15: 1207-1214
40 Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-279
41 Swisher EM, Lin KK, Oza AM. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017; 18: 75-87